Lucinactant (Discovery Laboratories).

  title={Lucinactant (Discovery Laboratories).},
  author={Ian R. Doyle},
  journal={IDrugs : the investigational drugs journal},
  volume={5 7},
  • Ian R. Doyle
  • Published in
    IDrugs : the investigational…
Discovery Laboratories Inc (formerly Acute Therapeutics Inc (ATI) is developing lucinactant, originally identified at the Scripps Research Institute and sublicensed from Johnson & Johnson, for the potential treatment of respiratory diseases [174059], [357077], [361765], [422819]. The company anticipated filing an NDA for lucinactant in 2002, and by March 2002, lucinactant was in two pivotal phase III international trials for respiratory distress syndrome (RDS) in premature infants, a phase III… CONTINUE READING